High expression of intestinal-type mucin (MUC2) in intraductal papillary mucinous neoplasms coexisting with extrapancreatic gastrointestinal cancers.
OBJECTIVE
It is known that intraductal papillary mucinous neoplasm (IPMN) is associated with a high incidence of extrapancreatic neoplasms. We tried to uncover the characteristics and gene expressions of IPMNs that coexist with other extrapancreatic gastrointestinal cancers.


METHODS
We retrieved the surgical specimens from 54 IPMN patients, including 7 cases of IPMNs that coexisted with extrapancreatic gastrointestinal cancers. The immunohistochemical staining (p21, Bcl-2, p53, intestinal-type secretory mucin [MUC2], and MUC5AC) and the pathological subtypes of the tumor papillae (the intestinal type, pancreaticobiliary type, null type, or unclassified type) were analyzed.


RESULTS
MUC2 expression was noticed more frequently in the IPMN coexisting with extrapancreatic cancers (6/7) than in the IPMN without extrapancreatic cancers (18/47; P = 0.04). There were no differences in p21 (P = 0.12), p53 (P = 0.25), and MUC5AC (P = 1.0) expressions between the 2 groups. IPMN with extrapancreatic cancers was noticed in all subtypes of papillae.


CONCLUSIONS
Regardless of the subtypes of papillae, transcription of the MUC2 might be related with the synchronous extrapancreatic gastrointestinal cancer development that is seen with IPMN. Therefore, careful systemic surveillance is needed to detect coexisting gastrointestinal cancer for all the subtypes of IPMN with MUC2 expression.
Lee
Sun-Young
SY
Department of Internal Medicine, Konkuk University College of Medicine, Seoul, Korea.
Choi
Dong Wook
DW
Jang
Kee-Taek
KT
Lee
Kyu Taek
KT
Choi
Seong Ho
SH
Heo
Jin Seok
JS
Lee
Jong Kyun
JK
Paik
Seung Woon
SW
Rhee
Jong Chul
JC
D021441:Carcinoma, Pancreatic Ductal / Q000150:complications / Q000473:pathology*; D002291:Carcinoma, Papillary / Q000150:complications / Q000473:pathology*; D003110:Colonic Neoplasms / Q000150:complications / Q000473:pathology; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D055262:Mucin-2; D009077:Mucins / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000150:complications*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000150:complications / Q000473:pathology*
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; C524625:MUC2 protein, human; D055262:Mucin-2; D009077:Mucins